Suppr超能文献

相似文献

1
Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.
Clin Gastroenterol Hepatol. 2018 Jun;16(6):800-808.e7. doi: 10.1016/j.cgh.2017.09.033. Epub 2017 Sep 28.
3
Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI.
Helicobacter. 2019 Feb;24(1):e12554. doi: 10.1111/hel.12554. Epub 2018 Nov 15.
6
Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
Eur J Clin Pharmacol. 2009 Jan;65(1):19-31. doi: 10.1007/s00228-008-0576-5. Epub 2008 Oct 17.
9
Combination drug therapy for gastroesophageal reflux disease.
Ann Pharmacother. 2002 May;36(5):912-6. doi: 10.1345/aph.10247.
10
[New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
Presse Med. 2004 Jun 19;33(11):746-54. doi: 10.1016/s0755-4982(04)98731-3.

引用本文的文献

1
Impact of Acid Suppressants on the Development of Infection and Possible Preventive Effects of Probiotic Formulations.
Infect Drug Resist. 2025 Aug 31;18:4593-4602. doi: 10.2147/IDR.S543864. eCollection 2025.
2
Diagnosis and Management of Gastroesophageal Reflux Disease: Current Insights.
Clin Exp Gastroenterol. 2025 Jul 8;18:149-162. doi: 10.2147/CEG.S507237. eCollection 2025.
3
Do the new ACG treatment guidelines have implications for Canada?
J Can Assoc Gastroenterol. 2025 May 6;8(3):85-88. doi: 10.1093/jcag/gwaf008. eCollection 2025 Jun.
4
Vonoprazan and proton pump inhibitors: Which is superior for eradication?
World J Gastroenterol. 2025 May 7;31(17):103156. doi: 10.3748/wjg.v31.i17.103156.
5
Oesophageal Dysmotility in a Patient with Charcot-Marie-Tooth Disease: Report and Literature Review.
Eur J Case Rep Intern Med. 2025 Mar 17;12(4):005219. doi: 10.12890/2025_005219. eCollection 2025.
7
Esophageal Disorders in the Older Adult.
Curr Treat Options Gastroenterol. 2025 Dec;23(1). doi: 10.1007/s11938-025-00468-6. Epub 2025 Feb 27.
8
Crises in Antimicrobial Stewardship: Misuse of Clarithromycin for Therapy.
Pharmacoepidemiology. 2024 Mar;3(1):82-93. doi: 10.3390/pharma3010006. Epub 2024 Feb 20.
9

本文引用的文献

2
Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole.
Therap Adv Gastroenterol. 2016 Nov;9(6):759-769. doi: 10.1177/1756283X16670073. Epub 2016 Sep 29.
3
Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study.
Therap Adv Gastroenterol. 2016 Sep;9(5):671-8. doi: 10.1177/1756283X16650156. Epub 2016 May 26.
5
Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
Adv Ther. 2016 Jul;33(7):1140-57. doi: 10.1007/s12325-016-0345-2. Epub 2016 Jun 10.
10
National use of proton pump inhibitors from 2007 to 2011.
JAMA Intern Med. 2014 Nov;174(11):1856-8. doi: 10.1001/jamainternmed.2014.2900.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验